<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Regimens for &lt;em&gt;Pneumocystis&lt;/em&gt; pneumonia prophylaxis in adults and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Regimens for <em>Pneumocystis</em> pneumonia prophylaxis in adults and adolescents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Regimens for <em>Pneumocystis</em> pneumonia prophylaxis in adults and adolescents</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Oral dose*</td> <td class="subtitle1">Selected adverse reactions</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Preferred regimen</td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td> <p>1 DS tablet daily<sup>¶</sup></p> <p class="indent1"><strong>OR</strong></p> 1 SS tablet daily<sup>Δ</sup></td> <td>Fever, rash, neutropenia, gastrointestinal upset, transaminase elevation</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Alternative regimens<sup>◊</sup></td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td>1 DS tablet three times per week<sup>Δ</sup></td> <td>Fever, rash, neutropenia, gastrointestinal upset, transaminase elevation</td> </tr> <tr> <td class="indent2" colspan="3"><strong>OR</strong></td> </tr> <tr> <td class="indent1">Dapsone</td> <td> <p>50 mg twice daily</p> <p class="indent1"><strong>OR</strong></p> 100 mg daily</td> <td>Fever, rash, gastrointestinal upset, methemoglobinemia, hemolytic anemia (check for G6PD deficiency)</td> </tr> <tr> <td class="indent2" colspan="3"><strong>OR</strong></td> </tr> <tr> <td class="indent1">Atovaquone suspension</td> <td>1500 mg orally once daily given with food<sup>Δ</sup></td> <td>Gastrointestinal distress, rash</td> </tr> <tr> <td class="indent2" colspan="3"><strong>OR</strong></td> </tr> <tr> <td class="indent1" colspan="3">Combination of:<sup>Δ</sup></td> </tr> <tr> <td class="indent3">Dapsone</td> <td>50 mg daily plus</td> <td>Fever, rash, gastrointestinal upset, methemoglobinemia, hemolytic anemia (check for G6PD deficiency)</td> </tr> <tr> <td class="indent3">Pyrimethamine</td> <td>50 mg weekly plus</td> <td>Folate deficiency, gastrointestinal upset, rash</td> </tr> <tr> <td class="indent3">Leucovorin</td> <td>25 mg weekly</td> <td>Rash, thrombocytosis, wheezing, anaphylactoid reactions</td> </tr> <tr> <td class="indent2" colspan="3"><strong>OR</strong></td> </tr> <tr> <td class="indent1" colspan="3">Combination of:<sup>Δ</sup></td> </tr> <tr> <td class="indent3">Dapsone</td> <td>200 mg weekly plus</td> <td>Fever, rash, gastrointestinal upset, methemoglobinemia, hemolytic anemia (check for G6PD deficiency)</td> </tr> <tr> <td class="indent3">Pyrimethamine</td> <td>75 mg weekly plus</td> <td>Folate deficiency, gastrointestinal upset, rash</td> </tr> <tr> <td class="indent3">Leucovorin</td> <td>25 mg weekly</td> <td>Rash, thrombocytosis, wheezing, anaphylactoid reactions</td> </tr> <tr> <td class="indent2" colspan="3"><strong>OR</strong></td> </tr> <tr> <td class="indent1">Aerosolized pentamidine</td> <td>300 mg monthly (via Respirgard II nebulizer)</td> <td>Cough, wheezing, extrapulmonary pneumocystosis</td> </tr> </tbody></table></div><div class="graphic_lgnd">A regimen that provides prophylaxis for PCP and toxoplasmosis should be administered to patients with HIV who are IgG seropositive for toxoplasmosis AND have a CD4 count &lt;100 cells/microL.</div><div class="graphic_footnotes"><p>DS: double-strength oral tablet, 160 mg trimethoprim with 800 mg sulfamethoxazole; G6PD: glucose-6-phosphate dehydrogenase; HIV: human immunodeficiency virus; IgG: immunoglobulin G; PCP: <em>Pneumocystis</em> pneumonia; SS: single-strength oral tablet, 80 mg trimethoprim with 400 mg sulfamethoxazole; TMP-SMX: trimethoprim-sulfamethoxazole.</p>
<p>* The doses recommended in the table are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</p>
<p>¶ This regimen is also the preferred regimen for prevention of toxoplasmosis.</p>
<p>Δ This regimen is considered an alternative regimen for prevention of toxoplasmosis.</p>
◊ Of the alternative regimens for prevention of PCP, TMP-SMX three times weekly is generally preferred. If patients cannot tolerate TMP-SMX, we prefer to use dapsone (or dapsone with pyrimethamine and leucovorin for patients who require prophylaxis for toxoplasmosis) rather than atovaquone. Dapsone is a sulfone that is usually tolerated by persons who have adverse reactions to TMP-SMX. However, in patients who have had serious reactions to TMP-SMX (eg, Stevens-Johnson syndrome/toxic epidermal necrolysis, rash with fever and systemic symptoms, serum sickness, or hemolytic anemia), it may be prudent to avoid dapsone. Aerosolized pentamidine should be used for PCP prophylaxis only when no other alternatives are available.</div><div class="graphic_reference">Adapted from: Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a> (Accessed on October 18, 2023).</div><div id="graphicVersion">Graphic 79988 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
